Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Good news has been scarce for this beaten-down drugmaker.

Up until recently, the stock has been a chronic underperformer.

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though ...

Pfizer's dividend safety hinges on free cash flow recovery in 2026, as the current payout consumes more cash than the company ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease, but the company could see ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...